Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.

Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q.

J Immunol Res. 2014;2014:268479. doi: 10.1155/2014/268479. Epub 2014 Apr 10.

PMID:
24818166
[PubMed - in process]
Free PMC Article
2.

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH.

Clin Cancer Res. 2007 Dec 15;13(24):7380-7.

PMID:
18094420
[PubMed - indexed for MEDLINE]
Free Article
3.

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.

Gold DV, Newsome G, Liu D, Goldenberg DM.

Mol Cancer. 2013 Nov 20;12(1):143. doi: 10.1186/1476-4598-12-143.

PMID:
24257318
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV.

Arch Pathol Lab Med. 2014 Feb;138(2):220-8. doi: 10.5858/arpa.2013-0056-OA.

PMID:
24476519
[PubMed - indexed for MEDLINE]
5.

Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.

Gold DV, Schutsky K, Modrak D, Cardillo TM.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.

PMID:
14506191
[PubMed - indexed for MEDLINE]
Free Article
6.

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.

Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, Salvadori PA, Giulianotti PC, Mosca F, Gold DV, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.

PMID:
7493369
[PubMed - indexed for MEDLINE]
Free Article
7.

Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.

Gold DV, Cardillo T, Goldenberg DM, Sharkey RM.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54.

PMID:
11418312
[PubMed - indexed for MEDLINE]
8.

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.

Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM.

Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.

PMID:
18559529
[PubMed - indexed for MEDLINE]
Free Article
9.

Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.

Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, Chang CH, Goldenberg DM.

J Nucl Med. 2009 Dec;50(12):2008-16. doi: 10.2967/jnumed.109.067686.

PMID:
19949026
[PubMed - indexed for MEDLINE]
Free Article
10.

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.

Cardillo TM, Blumenthal R, Ying Z, Gold DV.

Int J Cancer. 2002 Jan 20;97(3):386-92.

PMID:
11774294
[PubMed - indexed for MEDLINE]
11.

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin.

Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T.

Int J Cancer. 1994 Apr 15;57(2):204-10.

PMID:
7512537
[PubMed - indexed for MEDLINE]
12.

111In-Labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-d-Tyr-d-Lys(HSG)-d-Glu-d-Lys(HSG)-NH2 (IMP-288).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jun 29 [updated 2011 Aug 25].

PMID:
21882402
[PubMed]
Books & Documents
13.

Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer.

Alisauskus R, Wong GY, Gold DV.

Cancer Res. 1995 Dec 1;55(23 Suppl):5743s-5748s.

PMID:
7493339
[PubMed - indexed for MEDLINE]
Free Article
14.

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM.

Cancer. 2013 Feb 1;119(3):522-8. doi: 10.1002/cncr.27762. Epub 2012 Aug 16.

PMID:
22898932
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.

Cardillo TM, Ying Z, Gold DV.

Clin Cancer Res. 2001 Oct;7(10):3186-92.

PMID:
11595713
[PubMed - indexed for MEDLINE]
Free Article
16.

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.

Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM.

J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.

PMID:
16344318
[PubMed - indexed for MEDLINE]
Free Article
17.

Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4.

Gold DV, Cardillo T, Vardi Y, Blumenthal R.

Int J Cancer. 1997 May 16;71(4):660-7.

PMID:
9178823
[PubMed - indexed for MEDLINE]
18.

125I-Labeled trivalent, bispecific monoclonal antibody construct TF10 that targets mucin-1 and is reactive against a histamine-succinyl-glycine hapten IMP-288.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jun 29 [updated 2011 Aug 25].

PMID:
21882406
[PubMed]
Books & Documents
19.

Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.

Gold DV, Alisauskas R, Sharkey RM.

Cancer Res. 1995 Mar 1;55(5):1105-10.

PMID:
7866995
[PubMed - indexed for MEDLINE]
Free Article
20.

Detection of early-stage pancreatic adenocarcinoma.

Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-94. doi: 10.1158/1055-9965.EPI-10-0667. Epub 2010 Sep 1.

PMID:
20810605
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk